ReviewThe European respiratory journal2022
Asthma remission: what is it and how can it be achieved?
Review in The European respiratory journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07508280 (Effects of Energy Conservation Exercises Versus Circuit Training on Dyspnea, Functional Capacity and Quality of Life in Asthmatic Patients), which is not on this map. Cited by 138 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Effects of Energy Conservation Exercises Versus Circuit Training on Dyspnea, Functional Capacity and Quality of Life in Asthmatic Patients
Who cites it
138 citing papers in PubMed, 231 citations in OpenAlex.
- Clinical response and on-treatment clinical remission with tezepelumab in a broad population of patients with severe, uncontrolled asthma: results over 2 years from the NAVIGATOR and DESTINATION studies.The European respiratory journal · 2024Trial
- Asthma remission following inhaled treatments.ERJ open research · 2026Article
- Early response toward clinical remission with dupilumab in severe asthma: Real-world cohort.The journal of allergy and clinical immunology. Global · 2026Article
- Current perspectives on the psychological stress-immune axis in asthma: Pathophysiology, interventions, and significance for patient care.The World Allergy Organization journal · 2026Review
- A circulating odd-chain fatty acid biomarker signature discriminates pediatric allergic rhinitis with asthma from related allergic airway phenotypes.Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology · 2026Article
- Clinical Remission Trajectories Beyond 12 Months in Severe Asthma Patients Continuing a Single Biologic: A Real-World Single SANI Center Cohort.Medical sciences (Basel, Switzerland) · 2026Article
- Clinical Remission is Achievable for Adult Patients with Severe Asthma Receiving Mepolizumab: A European Retrospective Chart Review.Advances in therapy · 2026Article
- A four-year journey towards clinical remission and background therapies optimization with benralizumab: A retrospective analysis.The World Allergy Organization journal · 2026Article
- Criteria for Control and Remission of Respiratory Allergic Disease With Allergen Immunotherapy: A Delphi Consensus.Clinical and translational allergy · 2026Article
- Follow-up study on factors influencing the persistence of asthma in discharged children.BMC pediatrics · 2026Article
- Time to Rethink ICS Dosing in Pursuit of Asthma Clinical Remission: High-Dose ICS/LABA May Restore Short-Term Asthma Control When Medium Doses Fail.Journal of clinical medicine · 2026Article
- Artesunate-based macromolecular therapy attenuates neutrophilic asthma by targeting the BCAT1/Succinate/NLRP3 metabolite-immunity cascade.Journal of nanobiotechnology · 2026Article
- Current Practices and Variations Among Pediatric Severe Asthma Programs in the United States-The North American Severe Pediatric Asthma Consortium.Pediatric pulmonology · 2026Observational
- Add-on mepolizumab in patients with severe asthma on medium-dose inhaled corticosteroids.ERJ open research · 2026Article
- Mycoplasma pneumoniae infection impairs asthma control in pediatric patients and exacerbates allergic airway inflammation.Respiratory research · 2026Article
- Consensus of Korean Asthma Study Group on Definition of Clinical Remission in Severe Asthma: A Modified Delphi Study.Tuberculosis and respiratory diseases · 2026Article
- Clinical Remission in Severe T2-High Asthma in Real Life After Anti-IgE, Anti-IL-5 and Anti-IL5R: A Potential Role for CRP as a Biomarker.Clinical and translational allergy · 2026Article
- Baseline Composite Score for 12-Month Clinical Remission in Biologic-Treated Severe Asthma: Development of the Base4Score.Biomedicines · 2026Article
- Long-Term Clinical and Biological Outcomes of Biologic Therapy in Severe Asthma: 24-Month Real-World Cohort Study from Romania.Journal of clinical medicine · 2026Article
- Maternal 12-HETE is associated with childhood asthma and the responses to prenatal omega-3 supplementation.Cell reports. Medicine · 2026Article
78 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Asthma treatment goals currently focus on symptom and exacerbation control rather than remission. Remission is not identical to cure, but is a step closer. This review considers the current definitions of remission in asthma, the prevalence and predictors, the pathophysiology of remission, the possibility of achieving it using the available treatment options, and the future research directions. Asthma remission is characterised by a high level of disease control, including the absence of symptoms and exacerbations, and normalisation or optimisation of lung function with or without ongoing treatment. Even in those who develop a symptomatic remission of asthma, persistent pathological abnormalities are common, leading to a risk of subsequent relapse at any time. Complete remission requires normalisation or stabilisation of any underlying pathology in addition to symptomatic remission. Remission is possible as part of the natural history of asthma, and the prevalence of remission in the adult asthma population varies between 2% and 52%. The factors associated with remission include mild asthma, better lung function, better asthma control, younger age, early-onset asthma, shorter duration of asthma, milder bronchial hyperresponsiveness, fewer comorbidities and smoking cessation or never smoking. Although previous studies have not targeted treatment-induced remission, there is some evidence to show that the current long-term add-on therapies such as biologics and azithromycin can achieve some criteria for asthma remission on treatment, at least in a subgroup of patients. However, more research is required. Long-term remission could be included as a therapeutic goal in studies of asthma treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.